Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States

The safety and immunogenicity of four formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV), formulated at 1 or 4 μg with aluminum hydroxide (alum) or at 1 μg with an adjuvant system (AS01(E) or AS03(B)), were evaluated in a first-time-in-human, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Alexander C., Lin, Leyi, Martinez, Luis J., Ruck, Richard C., Eckels, Kenneth H., Collard, Alix, De La Barrera, Rafael, Paolino, Kristopher M., Toussaint, Jean-François, Lepine, Edith, Innis, Bruce L., Jarman, Richard G., Thomas, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462566/
https://www.ncbi.nlm.nih.gov/pubmed/28719287
http://dx.doi.org/10.4269/ajtmh.16-0634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462566/
https://www.ncbi.nlm.nih.gov/pubmed/28719287
http://dx.doi.org/10.4269/ajtmh.16-0634

Ejemplares similares